Skip to main content

Featured

5 Things to Know Today: TSX Recap, Oil Eases, Loonie Under Pressure & Alberta's Pipeline Announcement (July 3, 2026)

  Friday, July 3, 2026 Here's what's moving markets and your money this morning — from Bay Street to the pumps to Ottawa. 1. TSX gains as investors digest a mixed session The S&P/TSX Composite closed up 0.31% on Thursday at 34,966.67 points (+109.68), its first full trading day back after the Canada Day holiday. Financials were mixed — Brookfield edged higher while TD Bank slipped nearly 1% — but mining stocks got a lift as gold prices ticked up, with Barrick and Franco-Nevada both up more than 3%. Shopify was the standout, jumping over 5% after settling a dispute with Shopline. 2. Oil prices ease as Iran-US talks continue in Doha Crude prices pulled back further and are now trading closer to pre-conflict levels after another round of indirect US-Iran talks in Doha, even though the sides didn't reach a breakthrough. That's welcome news for anyone filling up this long weekend, and it's also easing some of the energy-driven inflation pressure that's been compl...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment